Introduction {#sec1_1}
============

It is estimated that in the United States, approximately 207,000 women were diagnosed with invasive breast cancer and approximately 40,000 women died from the disease in 2010 \[[@B1]\]. Between 1999 and 2005, 4--8% of women in the United States initially diagnosed with breast cancer were found to have metastatic disease \[[@B1]\]. The most common sites of breast cancer metastases are to bone, liver, brain, lung, and subcutaneous tissues. We report the use of endoscopic ultrasound (EUS) in establishing the diagnosis of recurrent breast cancer to an intraabdominal lymph node.

Case Report {#sec1_2}
===========

A 43-year-old female was diagnosed with invasive ductal carcinoma (modified Bloom-Richardson grade III, estrogen receptor negative, progesterone receptor negative, HER2/neu negative) of the left breast in 2008 by needle biopsy. She subsequently completed neoadjuvant therapy with cyclophosphamide, doxorubicin, and fluorouracil followed by an incomplete course of paclitaxel, which was discontinued prematurely due to neuropathy. At the time of left radical mastectomy, a 2.5 cm tumor with 7 out of 30 lymph nodes positive for malignancy was found (stage IIIC). Adjuvant therapy with radiation and docetaxel was subsequently completed. Computed tomography (CT) scans after adjuvant therapy were notable for an enlarging left upper lobe lung nodule concerning for metastatic disease. A subsequent positron emission tomography (PET) scan approximately 11 months after surgery demonstrated increased uptake of the pulmonary nodule seen on CT as well as in the right suprarenal region, which were both concerning for metastatic disease.

Due to the potential morbidity associated with sampling the lung nodule, EUS was requested to evaluate the intraabdominal finding on PET-CT. EUS demonstrated an isoechoic, well-defined 2.5 cm lymph node adjacent to the right kidney (fig. [1](#F1){ref-type="fig"}). Six passes were made with a 22 gauge fine needle aspiration needle under EUS guidance. The procedure duration was approximately 30 min. The patient tolerated the procedure well without complications and was discharged home 1 h after the procedure. The final cytologic impression was consistent with metastatic breast cancer with a similar immunohistochemical profile to the primary tumor. The patient is now receiving adjuvant carboplatin and gemcitabine therapy.

Discussion {#sec1_3}
==========

EUS is a well-recognized technique for staging and sampling various gastrointestinal malignancies. However, it has also been utilized for sampling ascites, the adrenal glands, as well as lymph nodes surrounding the esophagus, stomach, proximal duodenum, and rectum to aid in the diagnosis of malignancy \[[@B2], [@B3], [@B4], [@B5]\]. While EUS has previously been shown to be useful in diagnosing metastatic breast cancer to the esophagus, mediastinum, pancreas, stomach, and peritoneum \[[@B2], [@B3], [@B4], [@B6], [@B7], [@B8]\], there have been no reports to our knowledge describing the use of EUS for diagnosing an intraabdominal lymph node recurrence of breast cancer as in this case. Since the diagnosis of metastatic breast cancer was established by EUS, the patient was able to receive adjuvant therapy without undergoing more invasive procedures to sample the concerning pulmonary nodule.

In conclusion, the use of EUS should be considered as a less invasive modality for diagnosing primary or recurrent malignancies located adjacent to the upper or lower gastrointestinal tract.

Disclosure Statement {#sec1_4}
====================

The authors have no conflicts of interest to declare.

This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License ([www.karger.com/OA-license](http//www.karger.com/OA-license)), applicable to the online version of the article only. Distribution for non-commercial purposes only.
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